Abstract: The present disclosure provides a novel use of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). The present disclosure provides a composition that includes nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) for use in treating or preventing diseases, disorders, or symptoms related to activation of Hsd3b6 or a homolog thereof, and a method using the composition. In one embodiment, a composition including NMN or NR for use in improving the function of meibomian glands, and a method using the composition are provided.

Abstract: The purpose of the present invention is to provide a composition for preventing or treating neurotrophic keratitis. It is found that PACAP peptide exerts an effect to prevent corneal damages in a neurotrophic keratitis model and can promote neurite extension in a cultured nerve cell model. Furthermore, stability can be significantly increased by substituting a carboxyl group in an aspartic acid residue located at position-3 and/or position-8 in the sequence for PACAP by tetrazole. Provided are: a composition for preventing or treating neurotrophic keratitis, which contains PACAP peptide or stabilized PACAP peptide, and a neurite extension promoting agent.

Abstract: A peptide fragment isolated from proline-rich protein 4 (PRP4) has a neuroprotective action. The peptide can be a neuroprotective drug in a preventive or alleviative pharmaceutical composition. The peptide can be used in a neuropathic treatment.

Abstract: The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This is based on the finding that a peptide fragment isolated from proline-rich protein 4 (PRP4) has a neuroprotective action.

Abstract: A peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing the peptide, and a preventive or alleviative pharmaceutical composition. The peptide comprises proline-rich protein 4 having the sequence of SEQ ID NO:1 or a partial sequence thereof, or a modified sequence thereof, which has a neuroprotective action.

Abstract: The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This is based on the finding that a peptide fragment isolated from proline-rich protein 4 (PRP4) has a neuroprotective action.

Abstract: The main object of the present invention is to provide a novel compound which has a VEGF receptor tyrosine kinase inhibitory activity and is useful as an active ingredient for the treatment of diseases accompanying angiogenesis or edema, for example, age-related macular degeneration or the like. The present invention includes, for example, an alkynyl indazole derivative represented by the following general formula (I), a pharmaceutical acceptable salt thereof, and a medicine containing thereof.

Abstract: The main object of the present invention is to provide a novel compound which has a VEGF receptor tyrosine kinase inhibitory activity and is useful as an active ingredient for the treatment of diseases accompanying angiogenesis or edema, for example, age-related macular degeneration or the like. The present invention includes, for example, an alkynyl indazole derivative represented by the following general formula (I), a pharmaceutical acceptable salt thereof, and a medicine containing thereof.